Mild hypertension in people at low risk

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Martin, Stephen A ^a   Boucher, Marcy ^a   Wright, James M ^b   Saini, Vikas ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Lown Cardiovascular Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; GUANETHIDINE; PLACEBO;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BORDERLINE HYPERTENSION; DISEASE MARKER; HEALTH CARE COST; HUMAN; HYPERTENSION; LOW RISK PATIENT; PRACTICE GUIDELINE; PREHYPERTENSION; PRIORITY JOURNAL; BLOOD PRESSURE; ECONOMICS; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84908189175     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g5432     Document Type: Article

References (89)

1. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 2013;673:1-10.
2. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959-68.
3. National Ambulatory Medical Care Survey. 2010 summary tables. www. cdc. gov/nchs/ ahcd/web-tables. htm.
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-245.
5. World Health Organization. A global brief on hypertension: silent killer, global public health crisis. WHO, 2013.
6. Jones DS, Greene JA. The contributions of prevention and treatment to the decline in cardiovascular mortality: lessons from a forty-year debate. Health Aff (Millwood) 2012;31:2250-8.
7. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA 2013;310:699-705.
8. Pandya A, Gaziano TA, Weinstein MC, Cutler D. More Americans living longer with cardiovascular disease will increase costs while lowering quality of life. Health Aff (Millwood) 2013;32:1706-14.
9. Vital signs: avoidable deaths from heart disease, stroke, and hypertensive disease-United States, 2001-2010. MMWR Morb Mortal Wkly Rep 2013;62:721-7.
10. Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev 2012;8:CD006742.
11. Chobanian A V, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
12. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20.
13. Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol 2014;63:1230-8.
14. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014;32:3-15.
15. Wright JT, Fine LJ, Lackland DT, Ogedegbe G, Dennison-Himmelfarb CR, et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med 2014;160:499-503.
16. Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2013;29:528-42.
17. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ 2011;343:d4891.
18. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357.
19. Mitka M. Groups spar over new hypertension guidelines. JAMA 2014;311:663-4.
20. Guallar E, Laine C. Controversy over clinical guidelines: listen to the evidence, not the noise. Ann Intern Med 2014;160:361-2.
21. Krumholz HM, Lee TH. Redefining quality - implications of recent clinical trials. N Engl J Med 2008;358:2537-9.
22. Micheel C, Ball J, Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease. Evaluation of biomarkers and surrogate endpoints in chronic disease. National Academies Press, 2010.
23. Wallace J, Sharpey-Schafer E. Blood changes following controlled haemorrhage in man. Lancet 1941;393-5.
24. ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283:1967-75.
25. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
26. Slim HB, Black HR, Thompson PD. Older blood pressure medications - do they still have a place? Am J Cardiol 2011;108:308-16.
27. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393-401.
28. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009;2:CD001841.
29. Center for Drug Evaluation and Research. FDA drug safety communication: new warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). www. fda. gov/drugs/drugsafety/ucm300889. htm.
30. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev 2008;2:CD007066.
31. Parving H-H, Brenner BM, McMurray JJ V, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.
32. Filippone EJ, Foy A, Newman E. Goal-directed antihypertensive therapy: lower may not always be better. Cleve Clin J Med 2011;78:123-33.
33. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009;3:CD004349.
34. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011;123:2434-506.
35. Mizuno R, Fujimoto S, Saito Y, Okamoto, Y. Optimal antihypertensive level for improvement of coronary microvascular dysfunction: the lower, the better? Hypertension 2012;60:326-32.
36. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev 2009;4:CD000028.
37. Stamler J. Setting the TONE for ending the hypertension epidemic. JAMA 1998;279:878-9.
38. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14:32-8.
39. Port S, Demer L, Jennrich R, Garfinkel A. Systolic blood pressure and mortality. Lancet 2000;355:175-80.
40. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
41. Arterial "prehypertension": a useful concept for drug companies, useless for patients. Prescrire Int 2007;16:73-5.
42. McManus RJ, Caulfield M, Williams B. NICE hypertension guideline 2011: evidence based evolution. BMJ 2012;344:e181.
43. QuickStats: percentage distribution of blood pressure categories among adults aged >18 years, by race/ethnicity - National Health and Nutrition Examination Survey, United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007;56:611.
44. Moser M, Franklin SS. Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich) 2007;9:316-23.
45. Self-reported hypertension and use of antihypertensive medication among adults, United States, 2005-2009. MMWR Morb Mortal Wkly Rep 2013;62:237-44.
46. Jennings GLR, Touyz RM. Hypertension guidelines: more challenges highlighted by Europe. Hypertension 2013;62:660-5.
47. Villegas I, Arias IC, Botero A, Escobar A. Evaluation of the technique used by healthcare workers for taking blood pressure. Hypertension 1995;26:1204-6.
48. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American Heart Association. Circulation 2005;111:697-716.
49. Handler J, Zhao Y, Egan BM. Impact of the number of blood pressure measurements on blood pressure classification in US adults: NHANES 1999-2008. J Clin Hypertens (Greenwich) 2012;14:751-9.
50. Myers MG, Nelson MR, Head G. Automated office blood pressure measurement for routine clinical practice. Blood Press Monit 2006;11:59-62.
51. Myers MG. The great myth of office blood pressure measurement. J Hypertens 2012;30:1894-8.
52. Niiranen TJ, Hänninen M-R, Johansson J, Reunanen A, Jula AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. Hypertension 2010;55:1346-51.
53. Hänninen M-R, Niiranen TJ, Puukka PJ, Johansson J, Jula AM. Prognostic significance of masked and white-coat hypertension in the general population: the Finn-Home Study. J Hypertens 2012;30:705-12.
54. Magid DJ, Green BB. Home blood pressure monitoring: take it to the bank. JAMA 2013;310:40-1.
55. Cundiff DK. The economics and politics of drugs for mild hypertension. Health News Rev 2013. www. healthnewsreview. org/2013/11/the-economics-politics-of-drugs-for-mildhypertension/.
56. Centers for Medicare and Medicaid Services. The nation's health dollar, calendar year 2011: where it came from and where it went. 2013. www. cms. gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/ PieChartSourcesExpenditures2011. pdf.
57. Rodriguez CJ, Swett K, Agarwal SK, Folsom AR, Fox ER, Loehr LR, et al. Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study. JAMA Intern Med 2014;27157:1-10.
58. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97-104.
59. Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005;365:434-41.
60. Kerr AJ, Broad J, Wells S, Riddell T, Jackson R. Should the first priority in cardiovascular risk management be those with prior cardiovascular disease? Heart 2009;95:125-9.
61. Vital signs: awareness and treatment of uncontrolled hypertension among adults - United States, 2003-2010. MMWR Morb Mortal Wkly Rep 2012;61:703-9.
62. Marshall T. Evaluating national guidelines for prevention of cardiovascular disease in primary care. J Eval Clin Pract 2005;11:452-61.
63. Naci H, Ioannidis JPA. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 2013;347:f5577.
64. Eckel RH, Jakicic JM, Ard JD, Hubbard VS, de Jesus JM, Lee I-M, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 suppl 2):S76-99.
65. He J, Muntner P, Chen J, Streiffer RH, Whelton PK. Factors associated with hypertension control in the general population of the United States. Arch Intern Med 2002;162:1051-8.
66. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011;86:304-14.
67. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med 2012;172:1739-44.
68. Salvi F, Marchetti A, D'Angelo F, Boemi M, Lattanzio F, Cherubini A. Adverse drug events as a cause of hospitalization in older adults. Drug Saf 2012;35 (suppl 1):29-45.
69. Muller M, Jochemsen HM, Visseren FLJ, Grool AM, Launer LJ, van der Graaf Y, et al. Low blood pressure and antihypertensive treatment are independently associated with physical and mental health status in patients with arterial disease: the SMART study. J Intern Med 2013;274:241-51.
70. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-8.
71. Kovesdy CP, Bleyer AJ, Molnar MZ, Ma JZ, Sim JJ, Cushman WC, et al. Blood pressure and mortality in US Veterans with chronic kidney disease: a cohort study. Ann Intern Med 2013;159:233-42.
72. Bagul NB, Kirkham JJ. The reporting of harms in randomized controlled trials of hypertension using the CONSORT criteria for harm reporting. Clin Exp Hypertens 2012;34:548-54.
73. Eddy DM, Adler J, Morris M. The "global outcomes score": a quality measure, based on health outcomes, that compares current care to a target level of care. Health Aff (Millwood) 2012;31:2441-50.
74. Woolhandler S, Ariely D, Himmelstein DU. Why pay for performance may be incompatible with quality improvement. BMJ 2012;345:e5015.
75. Hutchison B. Pay for performance in primary care: proceed with caution, pitfalls ahead. Health Policy 2008;4:10-22.
76. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
77. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH., Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
78. Osher E, Greenman Y, Tordjman K, Kisch E, Shenkerman G, Koffler M, et al. Attempted forced titration of blood pressure to <130/85 mm Hg in type 2 diabetic hypertensive patients in clinical practice: the diastolic cost. J Clin Hypertens 2006;8:29-34.
79. Lipsitz LA. A 91-year-old woman with difficult-to-control hypertension: a clinical review. JAMA 2013;310:1274-80.
80. American Heart Association backs current BP treatments. 2014. www. heart. org/ HEARTORG/Conditions/HighBloodPressure/PreventionTreatmentofHighBloodPressure/ American-Heart-Association-backs-current-BP-treatments-UCM-459129-Article. jsp.
81. Krumholz HM. Three things to know about the new blood pressure guidelines. New York Times 2013 Dec 18. http://well. blogs. nytimes. com/2013/12/18/3-things-to-know-aboutthe-new-blood-pressure-guidelines/.
82. Minority report: five guideline authors reject change in blood pressure goal. www. forbes. com/sites/larryhusten/2014/01/13/minority-report-five-guideline-authors-reject-change-inblood-pressure-goal/.
83. Marshall TP. Blood pressure variability: the challenge of variation. Am J Hypertens 2008;21:3-4.
84. Villegas I, Arias IC, Botero A, Escobar A. Evaluation of the technique used by health-re workers for taking blood pressure. Hypertension 1995;26:1204-6.
85. Fishman PA, Anderson ML, Cook AJ, Ralston JD, Catz SL, Carlson J, et al. Accuracy of blood pressure measurements reported in an electronic medical record during routine primary care visits. J Clin Hypertens 2011;13:821-8.
86. Yarows SA. Two numbers to assess hypertension control, simple? Maybe not. J Am Soc Hypertens 2012;6:159.
87. Burgess SE, MacLaughlin EJ, Smith PA, Salcido A, Benton TJ. Blood pressure rising: differences between current clinical and recommended measurement techniques. J Am Soc Hypertens 2011;5:484-8.
88. Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D. Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 2008;52:1-9.
89. Clark CE, Horvath IA, Taylor RS, Campbell JL. Doctors record higher blood pressures than nurses: systematic review and meta-analysis. Br J Gen Pract 2014;64:e223-32.